Article (Scientific journals)
Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma.
Van Hulst, Glenn; Jorssen, Joseph; Jacobs, Nathalie et al.
2022In European Respiratory Journal
Peer Reviewed verified by ORBi
 

Files


Full Text
InPress_13993003.00935-2021.full.pdf
Author preprint (3.92 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Neutralising antibodies against the cytokine interleukin (IL)-5 have become widely used for the control of severe eosinophilic asthma. Remarkably, patients receiving neutralising anti-IL5 biological therapies retain a very stable population of residual blood eosinophils. Whether these residual eosinophils are endowed with particular biological activity has not yet been studied but is of importance in predicting potential long-term effects of IL5 neutralisation in patients. To tackle the effect of IL5 depletion on residual eosinophils, we used a comparative RNA-sequencing approach and compared the gene expression program of eosinophils arising in IL5-depleted or IL5-replete human or murine hosts, at steady-state in vivo and following in vitro stimulation with the eosinophil-activating alarmin IL33. We compared blood eosinophils from patients with severe allergic eosinophilic asthma treated with anti-IL5 mepolizumab therapy to those of healthy controls and matched asthma patients receiving anti-IgE omalizumab therapy. We made similar comparisons on bone marrow eosinophils from mice genetically deficient or not for IL5. We report that restriction of IL5 availability did not elicit any detectable transcriptional response in steady-state residual eosinophils in mepolizumab-treated patients or IL5-deficient mice, and influenced only a handful of genes in their response to IL33. Together, these results support the notion that treatment with IL5 neutralising antibodies spares a pool of circulating residual eosinophils largely resembling those of healthy individuals.
Disciplines :
Immunology & infectious disease
Author, co-author :
Van Hulst, Glenn ;  Université de Liège - ULiège > GIGA I3 - Cellular and Molecular Immunology
Jorssen, Joseph  ;  Université de Liège - ULiège > GIGA I3 - Cellular and Molecular Immunology
Jacobs, Nathalie  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Virologie
Henket, Monique 
Louis, Renaud ;  Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Schleich, Florence ;  Université de Liège - ULiège > Département des sciences de la motricité > Département des sciences de la motricité
Bureau, Fabrice ;  Université de Liège - ULiège > Vice-Recteur à la Recherche
Desmet, Christophe  ;  Université de Liège - ULiège > GIGA I3 - Cellular and Molecular Immunology
Language :
English
Title :
Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma.
Publication date :
2022
Journal title :
European Respiratory Journal
ISSN :
0903-1936
eISSN :
1399-3003
Publisher :
European Respiratory Society, United Kingdom
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org.
Available on ORBi :
since 23 November 2021

Statistics


Number of views
143 (23 by ULiège)
Number of downloads
11 (11 by ULiège)

Scopus citations®
 
12
Scopus citations®
without self-citations
11
OpenCitations
 
4

Bibliography


Similar publications



Contact ORBi